These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27466395)

  • 1. Understanding age and race disparities in the application of sentinel lymph node biopsy in breast cancer.
    Radhakrishnan A; Silverman P; Pollack CE; Pfoh ER; Shenk R; Thompson CL
    J Investig Med; 2016 Dec; 64(8):1241-1245. PubMed ID: 27466395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
    Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
    J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.
    Reeder-Hayes KE; Bainbridge J; Meyer AM; Amos KD; Weiner BJ; Godley PA; Carpenter WR
    Breast Cancer Res Treat; 2011 Aug; 128(3):863-71. PubMed ID: 21340480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer.
    Yen TWF; Li J; Sparapani RA; Laud PW; Nattinger AB
    Medicine (Baltimore); 2016 Aug; 95(31):e4392. PubMed ID: 27495053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rural and urban disparities in the evolution of sentinel lymph node utilization in breast cancer.
    Arrington AK; Kruper L; Vito C; Yim J; Kim J; Chen SL
    Am J Surg; 2013 Nov; 206(5):674-81. PubMed ID: 24035212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphedema following breast cancer treatment, including sentinel lymph node biopsy.
    Armer J; Fu MR; Wainstock JM; Zagar E; Jacobs LK
    Lymphology; 2004 Jun; 37(2):73-91. PubMed ID: 15328760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the quality of sentinel lymph node biopsy (SLNB) for breast cancer: a population-based evaluation.
    Wells B; Saskin R; Wright F; McCready D; Quan ML
    Ann Surg Oncol; 2013 Feb; 20(2):615-9. PubMed ID: 22941174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.
    Yen TW; Hunt KK; Ross MI; Mirza NQ; Babiera GV; Meric-Bernstam F; Singletary SE; Symmans WF; Giordano SH; Feig BW; Ames FC; Kuerer HM
    J Am Coll Surg; 2005 Apr; 200(4):516-26. PubMed ID: 15804465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
    Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
    J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States.
    Bilimoria KY; Balch CM; Wayne JD; Chang DC; Palis BE; Dy SM; Lange JR
    J Clin Oncol; 2009 Apr; 27(11):1857-63. PubMed ID: 19273706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society.
    Park HS; Chae BJ; Song BJ; Jung SS; Han W; Nam SJ; Youn HJ; Ko BK; Kim DW;
    Ann Surg Oncol; 2014 Apr; 21(4):1231-6. PubMed ID: 24318094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study found that peripheral lymph node sampling reduced the false-negative rate of sentinel lymph node biopsy for breast cancer.
    Han C; Yang B; Zuo WS; Liu YS; Zheng G; Yang L; Zheng MZ
    Chin J Cancer; 2016 Apr; 35():35. PubMed ID: 27044285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.
    Del Bianco P; Zavagno G; Burelli P; Scalco G; Barutta L; Carraro P; Pietrarota P; Meneghini G; Morbin T; Tacchetti G; Pecoraro P; Belardinelli V; De Salvo GL;
    Eur J Surg Oncol; 2008 May; 34(5):508-13. PubMed ID: 17614245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE;
    Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology.
    Luini A; Galimberti V; Gatti G; Arnone P; Vento AR; Trifirò G; Viale G; Rotmensz N; Fernandez JR; Gilardi D; Paganelli G
    Breast Cancer Res Treat; 2005 Jan; 89(2):159-63. PubMed ID: 15692758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging.
    Vanderveen KA; Schneider PD; Khatri VP; Goodnight JE; Bold RJ
    Ann Surg Oncol; 2006 Nov; 13(11):1450-6. PubMed ID: 17009150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of clinicopathological factors associated with false-negative rate of sentinel lymph node biopsy in breast cancer patients: experience of a single center].
    Yang B; Zheng G; Zuo WS; Yang L; Wang YS; Zheng MZ; Liu YS; Yu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):389-93. PubMed ID: 24054019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
    van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
    Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.
    McLaughlin SA; Wright MJ; Morris KT; Giron GL; Sampson MR; Brockway JP; Hurley KE; Riedel ER; Van Zee KJ
    J Clin Oncol; 2008 Nov; 26(32):5213-9. PubMed ID: 18838709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.